IP Library Granted Patent US 7,381,736
Granted Patent B2
US 7,381,736 · App. 11/219,402 · Granted Jun 3, 2008

Thiazole and thiadiazole inhibitors of tyrosine phosphatases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,381,736
App. No.
11/219,402
Granted
Jun 3, 2008
Kind
B2
Abstract

Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B.

Claims (70)

1. A compound that has formula II:

or a pharmaceutically acceptable salt, ester, enol ether, enol ester, solvate or hydrate thereof, wherein:

D is

E is CH 2 ;

s is 0;

R 8 and R 9 are H;

R 10 is halo;

R 11 is halo;

R 12 is H;

R 13 is CF 2 PO 3 H 2 ;

R 14 is halo;

R 15 is H;

R 16 is NHC(O)COOH or COOH;

and

R 17 is COO-alkyl.

2. The compound of claim 1 , wherein D is

E is CH 2 ;

s is 0;

R 8 and R 9 are H;

R 10 Cl;

R 11 is Cl;

R 12 is H;

R 13 is CF 2 PO 3 H 2 ;

R 14 is Cl or Br;

R 15 is H;

R 16 NHC(O)COOH or COOH; and

R 17 is COOMe.

3. The compound of claim 1 , wherein R 10 is Cl.

4. The compound of claim 1 , wherein R 11 is Cl.

5. The compound of claim 1 , wherein R 13 is CF 2 PO 3 H 2 .

6. The compound of claim 1 , wherein R 14 is Br.

7. The compound of claim 1 , wherein R 15 is H.

8. The compound of claim 1 , wherein R 16 is NHC(O)COOH or COOH.

9. The compound of claim 1 , wherein R 17 is COOMe.

10. The compound of claim 1 , wherein the compound is:

N-(4-{2-[[3-Bromo-4-(difluoro-phosphono-methyl)-benzyl]-(3 ,4-dichloro-phenyl)-amino]-thiazol-4-yl}-phenyl)-oxalamic acid.

11. The compound of claim 1 , wherein R 8 is H, R 9 is H, R 10 is Cl, R 11 is Cl, R 12 is H, R 13 is CF 2 PO 3 H 2 , R 14 is Br, R 15 is H, R 16 is NHC(O)COOH, R 17 is COOMe and s is zero (0).

12. A compound that has formula II:

or a pharmaceutically acceptable salt, ester, enol ether, enol ester, solvate or hydrate thereof, wherein:

D is

E is CH 2 ;

s is 0;

R 8 and R 9 are H;

R 10 is halo;

R 11 is halo;

R 12 is H;

R 13 is CF 2 PO 3 H 2 ;

R 13 is CF 2 PO 3 H 2 ;

R 14 is halo;

R 15 is H;

R 16 is NHC(O)COOH; and

R 17 is H or, COO-alkyl.

13. The compound of claim 12 , wherein D is

E is CH 2 ;

s is 0;

R 8 and R 9 are H;

R 10 is Cl;

R 11 is Cl;

R 12 is H;

R 13 is CF 2 PO 3 H 2 ;

R 14 is Cl or Br;

R 15 is H;

R 16 is NHC(O)COOH; and

R 17 is H or COOMe.

14. The compound of claim 12 , wherein R 10 is Cl.

15. The compound of claim 12 , wherein R 11 is Cl.

16. The compound of claim 12 , wherein R 14 is Br.

17. The compound of claim 12 , wherein R 17 is H or COOMe.

18. The compound of claim 17 , wherein R 17 is H.

19. The compound of claim 17 , wherein R 17 is COOMe.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2007
From: PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP; CADUCEUS PRIVATE INVESTMENTS, L.P.; GEIGY, JUERG F.; SECURITY PACIFIC FINANCE, LTD.; GILLIN, ARNE J.; ORBIMED ASSOCIATES L.L.C.; BIOTECHNOLOGY DEVELOPMENT FUND II, LP; MAC & CO.; BURRILL AGBIO CAPITAL FUND, L.P.; BURRILL BIOTECHNOLOGY CAPITAL, L.P.; BIOTECHNOLOGY DEVELOPMENT FUND, LP; URVATER, RONALD M.; BOHR, JAKOB; DANSK KAPITALANTAEG AKTIESELSKAG; PERNET, ERNEST; INGLEWOOD VENTURES L.P.
To: METABASIS THERAPEUTICS, INC.
Reel/Frame 018859/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2006
From: CHERUVALLATH, ZACHARIA S.; LOWETH, COLIN J.; NUTT, RUTH F.; RIDEOUT, DARRYL; SEMPLE, JOSEPH E.; WANG, JING; WU, FEIYUE; MYLVAGANAM, SHANKARI; ZHU, HENGYI; SUN, JIANZHONG
To: CENGENT THERAPEUTICS, INC.
Reel/Frame 018270/0230 →